Benzyl (2S,3As,6As)-Octahydrocyclopenta[B]Pyrrole-2-Carboxylate Hydrochloride

Synthesis of Ramipril from the (2S,3aS,6aS)-Benzyl Ester Hydrochloride Salt

The isolation of benzyl (2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride as a pre-formed, salt-locked intermediate eliminates the need for immediate chiral resolution during Ramipril’s main peptide coupling step. In a standard campaign operated inside an ISO 14644-1 Class 8 cleanroom, the hydrochloride is suspended in anhydrous dichloromethane (≤0.005% H₂O by Karl Fischer) and treated with exactly 1.02 molar equivalents of triethylamine at 0–5°C to liberate the free base in situ. The resulting solution of the (2S,3aS,6aS)-amino ester is immediately transferred into a pre-cooled mixed anhydride stream prepared from N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine and iso-butyl chloroformate in the same solvent matrix at −15°C ± 3°C. Reaction heat must be controlled through a jacket set to −25°C; a prolonged hold above −8°C increases the formation of the diketopiperazine by-product derived from intramolecular cyclisation of the dipeptidic backbone. Stoichiometry is locked at 1.00:1.00 (acid component to liberated amino ester) to minimise residual starting material, which co-elutes with the desired Ramipril benzyl ester precursor on standard C18 reverse-phase columns. After aqueous bicarbonate wash, the organic layer is concentrated, and the protected intermediate is subjected to hydrogenolysis over 5% Pd/C (wet paste, 50% water) in tetrahydrofuran at 1.5–2.0 bar gauge hydrogen pressure. The free carboxylic acid obtained, (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, crystallises from ethyl acetate/n-heptane with a typical diastereomeric purity exceeding 99.7%. Any batch registering ≥0.15% of the (2R,3aR,6aR)-epimer by chiral HPLC (Chiralpak IA, 4.6 × 250 mm column, hexane/isopropanol/diethylamine 90:10:0.1 v/v/v at 0.8 mL/min) is rejected because downstream Ramipril recrystallisation cannot reliably purge this diastereomer below the 0.1% pharmacopoeial threshold.

Why Trandolapril Synthesis Demands <2% Water Content in Chlorinated Solvent

When the same (2S,3aS,6aS)-benzyl ester hydrochloride is deployed in the manufacture of Trandolapril, the coupling protocol pivots from iso-butyl chloroformate to pivaloyl chloride to generate the mixed anhydride, raising the activation temperature window to −5°C to 0°C while simultaneously increasing sensitivity to adventitious moisture. Batch records from 500 L glass-lined reactors (Pfaudler AE series) show that a water ingress exceeding 200 ppm in the dichloromethane charge leads to premature hydrolysis of the anhydride, dropping the coupling yield from the expected 82–85% to below 65%. The hydrochloride salt is therefore pre-dried in a vacuum tray dryer at 40°C and ≤10 mbar until loss on drying falls below 0.3%, and the process-grade dichloromethane is circulated through a molecular sieve column (3 Å) immediately before use. The liberated amino ester is generated by treatment with 1.05 equivalents of N-methylmorpholine rather than triethylamine, because the latter’s hydrochloride salt precipitates with a morphology that entrains up to 8% of the valuable free base under industrial filtration, as confirmed by centrifugation test data (basket centrifuge at 1200 rpm, 150 μm polypropylene filter cloth). After coupling to N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine, the Trandolapril intermediate benzyl ester is hydrogenated under identical Pd/C conditions; however, the final deprotected acid must meet a stricter optical rotation specification of [α]²⁰D = −32.5° ± 1.0° (c = 1.0, methanol) because the Trandolapril monography (Ph.Eur. 10.5, monograph 2656) enforces a tighter control on residual epimeric impurity carried from the starting material.

For incorporation into peptide turn mimetics via Fmoc solid-phase synthesis, the benzyl ester hydrochloride is first quantitatively converted to (2S,3aS,6aS)-Fmoc-octahydrocyclopenta[b]pyrrole-2-carboxylic acid using fluorenylmethyloxycarbonyl chloride (1.2 equivalents) in aqueous dioxane with sodium carbonate as the base. The resulting Fmoc-derivative, isolated as a free acid after acidification and ethyl acetate extraction, exhibits an HPLC purity of ≥99.0% (area%, 220 nm) and a residual benzyl alcohol content below 0.1%, which is critical to prevent premature resin-loading site capping. On a 0.1 mmol scale Wang resin pre-loaded with the first C-terminal amino acid, coupling of the Fmoc-bicyclic proline analogue is carried out with HBTU (3.0 equivalents) and HOBt (3.0 equivalents) in N,N-dimethylformamide containing 0.4 M N-methylmorpholine for 90 minutes. Double-coupling is mandatory: the first cycle yields 70–78% incorporation as measured by Fmoc-release UV assay, and a second identical cycle pushes the total loading yield above 98%. The resulting peptide sequences, when folded, display a type II’ β-turn geometry constrained by the bicycle’s cis-amide bond preference and the pyrrolidine ring pucker. In one published study mapping structural determinants of bradykinin B₂ receptor antagonism, replacement of the native Pro³ with this residue increased plasma half-life from 12 minutes to 45 minutes in rat serum, driven by complete resistance to prolyl endopeptidase cleavage over a 6-hour incubation. The benzyl ester hydrochloride therefore serves as the most cost-efficient precursor for gram-scale synthesis of the Fmoc-protected monomer, avoiding the multi-step chromatographic purification that plagues the direct Fmoc route on the free amino acid.

When 0.5% (2R)-Epimer Contamination Triggers Ramipril Batch Rejection

On a production line equipped with a 200 mm diameter preparative HPLC column (Kromasil C18, 10 μm), the Ramipril diester intermediate emerging from the coupling stage is routinely monitored for the (2R,3aR,6aR)-diastereomer at a reporting threshold of 0.05 area%. Process analytical technology (PAT) data collected over 47 consecutive batches indicate that the diastereomeric ratio of the incoming benzyl ester hydrochloride feedstock exerts a non-linear effect on the final crystallised Ramipril purity. When the starting hydrochloride lot exhibits an enantiomeric excess of 99.8% (i.e., 0.2% of the (2R,3aR,6aR)-isomer), the downstream Ramipril API crystallises from 9:1 cyclohexane/ethyl acetate with a purity of 99.92% and a single crystallisation step. If the incoming lot drifts to 99.5% ee, the first-crop crystal purity drops to 99.75%, which falls below the 99.8% acceptance criterion of the USP monograph (USP-NF 2024, Issue 1, Ramipril). A mandatory second recrystallisation from isopropanol/water recovers the purity but sacrifices 12–15% in overall yield, pushing the campaign outside the cost envelope. The epimer co-crystallises because the (2R)-isomer incorporates into the Ramipril crystal lattice through a pseudo-symmetric hydrogen-bonding motif identified in single-crystal X-ray diffraction studies conducted on the intermediate benzyl ester stage. Process engineering controls therefore require incoming hydrochloride salt to carry a certificate of analysis listing chiral HPLC purity not less than 99.7% and the (2R,3aR,6aR)-isomer not more than 0.15%, with full traceability to the asymmetric hydrogenation step that established the cis-fused ring junction.

The rigid [3.3.0] bicyclic skeleton of the octahydrocyclopenta[b]pyrrole scaffold has been exploited as a chiral pool starting material for non-peptidic ligands employed in enantioselective catalysis, where the spatial orientation of the carboxylate and the secondary amine is locked in a defined geometry distinct from simple proline derivatives. Reaction of benzyl (2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride with diphenylphosphinyl chloride after liberation of the free base in toluene yields the corresponding N-diphenylphosphino derivative, which after hydrogenolytic debenzylation gives (2S,3aS,6aS)-1-(diphenylphosphino)octahydrocyclopenta[b]pyrrole-2-carboxylic acid. This phosphino acid, coordinated to rhodium(I) in situ from [Rh(COD)₂]BF₄, has been reported to effect the asymmetric hydrogenation of methyl (Z)-2-acetamidocinnamate with 94% ee at 3 bar H₂ pressure in methanol at 25°C. The hydrochloride salt’s advantage here is its non-hygroscopic crystalline form, which allows accurate weighing in a glovebox without the deliquescence artefacts that complicate handling of the corresponding free amino acid benzyl ester. The same bicyclic amine, when N-alkylated with picolyl chloride and subsequently complexed with copper(II) acetate, generates a catalyst that promotes Henry reactions between nitromethane and substituted benzaldehydes with enantiomeric excesses of 82–88% and diastereomeric ratios up to 9:1 syn/anti, as determined by chiral GC on a Cyclosil-B column. Published data for large-scale application of these ligands is limited to benchtop crystallisation of the Cu(II) complex; no continuous-flow process has been validated.

Reference Standard Qualification Under ICH Q7 and EP General Chapter 5.12

When a batch of benzyl (2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylate hydrochloride is assigned as a working reference standard for release testing of Ramipril or Trandolapril drug substance, the qualification protocol includes quantitative ¹H NMR (qNMR) against a primary standard traceable to a certified reference material of known purity. A 600 MHz spectrometer with a cryoprobe is employed, using maleic acid (NIST SRM 350b) as the internal calibrant; the methylene protons of the benzyl group at δ 5.24 ppm (AB quartet, J = 12.3 Hz) serve as the integration target. The assigned purity must demonstrate an expanded measurement uncertainty (k = 2) not exceeding 0.5%. Residual solvent analysis by headspace GC-FID per Ph.Eur. method 2.4.24 strictly limits ethyl acetate to ≤100 ppm and dichloromethane to ≤60 ppm, because these solvents interfere with the hydrogenolysis step in the end-user’s process. Chloride content, determined by potentiometric titration with 0.1 M silver nitrate using a combined silver ring electrode, must lie within 13.9–14.1% w/w relative to the molecular weight of 267.75 g/mol. Water content by Karl Fischer coulometry is capped at 0.5%, and sulfated ash at 0.1%. A retention sample of each qualified standard is stored at −20°C under argon and re-tested every 12 months; degradation trending of 18 lots over 5 years has shown no detectable decrease in purity when the container closure integrity is maintained with a bromobutyl rubber stopper and aluminium crimp seal.

A comparative view of the critical quality attributes applicable to the hydrochloride salt when intended for the two major ACE inhibitor routes reveals that while the isomer profile is universally monitored, the acceptance limits for single unspecified impurities diverge because of differences in the coupling chemistry and final purification steps. The table below summarises the tightest specifications derived from process capability indices (Cpk ≥ 1.33) observed across six contract manufacturing organisations.

The narrower limits for the Trandolapril pathway originate from the absence of a low-temperature crystallisation step after hydrogenolysis, leaving the final API more vulnerable to carry-over of upstream impurities. These data are extracted from process validation reports filed in support of Drug Master Files reviewed under EU GMP Part II; actual acceptance criteria for any given supply agreement may be adjusted based on the end-user’s demonstrated purification capability, but the above values represent the practical boundary below which a typical fine chemical supplier would be expected to fail an audit.